ArticleMalaria journal2025
Wealth-based inequalities in the uptake of three or more doses of intermittent preventive treatment in pregnancy in West Africa, 2015-2021.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends, regional disparities, and projected burden of anemia among women of reproductive age in Ghana, 2000-2030.Reproductive health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaemia in pregnancy remains a major public health challenge in sub-Saharan Africa, contributing to adverse birth outcomes, including low birth weight and neonatal mortality. The World Health Organization (WHO) recommends the uptake of intermittent preventive treatment during pregnancy with at least three doses of sulfadoxine-pyrimethamine (IPTp-SP3) to reduce these adverse outcomes. Achieving equitable distribution of IPTp-SP3 is essential for advancing Sustainable Development Goal 3 (SDG3), which aims to achieve universal health coverage and equitable access to healthcare services for all men and women. However, continued disparities in the uptake of IPTp3 across socioeconomic groups are evident in many African countries. This study, therefore, investigates wealth-based inequalities in IPTp-SP3 coverage across 15 West African countries.
methodsUsing the WHO Health Equity Assessment Toolkit (HEAT), the study analysed secondary data drawn from the Demographic and Health Surveys (DHS), Malaria Indicator Surveys (MIS) and Multiple Indicator Cluster Surveys (MICS) conducted from 2015 to 2021, across 15 West African countries. Four measures of inequalities: Absolute Difference (D), Prevalence Ratio(R), Population Attributable Risk(PAR) and Population Attributable Fraction(PAF) were used to assess wealth-related inequalities in IPTp-SP3 coverage.
resultsThe lowest IPTp-SP3 coverage, 11.2% was recorded in Mauritania, whilst Burkina Faso recorded the highest coverage of 57.7%. The results revealed substantial wealth-related inequalities. IPTp-SP3 coverage was high among the population's richest quintiles in Guinea (D = 30.3%), Togo (D = 27.6%) and Benin (D = 17.6%). Paradoxically, in Liberia (D = - 4.5%), Nigeria (D = - 4.4%), and Sierra Leone (D = - 3.1%), the poorest quintiles experience the highest IPTp-SP3 coverage compared to the richest quintiles. Countries with the greatest potential national increase in IPTp-SP3 coverage if the poorer quintiles had the same level of access as the richest were Togo (17.3), Guinea (17.2) and Senegal (6.3) percentage points. However, near-equitable access to IPTp-SP3 was observed in Liberia, Nigeria and Sierra Leone.
conclusionWealth-based inequalities continue to hinder IPTp-SP3 uptake in West Africa. Addressing these disparities require targeted equity-driven strategies to improve coverage among pregnant women and towards achieving the objectives of SDG 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.